Most Read Articles
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Prostate cancer treatment heightens risk of dementia

30 Aug 2020

Prostate cancer patients receiving treatment with androgen deprivation therapy (ADT) are at increased risk of developing all-cause dementia or Alzheimer’s disease, a study has found.

Researchers looked at 100,414 men aged ≥66 years (median, 73 years; 84 percent white) who were diagnosed with locally advanced prostate cancer (cT1–cT4). None of them had a history of stroke, dementia, and use of psychiatric services.

In total, 37,911 men (38 percent) received ADT within 6 months of diagnosis, of whom 19,854 (53 percent) used ADT for >7 months. Compared with nonusers, ADT recipients were older (median age, 75 vs 72 years) at diagnosis, more likely to have received radiotherapy (64 percent vs 37 percent), have more comorbidities (≥2: 38 percent vs 31 percent), and have more advanced clinical tumour stage

Over 36 months of follow-up, 3,988 men were diagnosed with dementia, 1,797 developed Alzheimer’s, and 2,208 men utilized psychiatric services. These outcomes occurred more frequently among men exposed vs not exposed to ADT (dementia: 5.1 percent vs 3.3 percent; Alzheimer’s: 2.4 percent vs 1.4 percent; use of psychiatric services: 2.5 percent vs 2.0 percent).

Inverse-probability weighted Fine-Gray model showed that receipt of any pharmacologic ADT conferred a 17-percent higher risk of all-cause dementia (hazard ratio [HR], 1.17, 95 percent confidence interval [CI], 1.07–1.27), 23-percent higher risk of Alzheimer’s (HR, 1.23, 95 percent CI, 1.11–1.37), and 10-percent higher risk of psychiatric services use, although this was not significant (HR, 1.10, 95 percent CI, 1.00–1.22).

The risk was more pronounced among men with longer ADT exposure (≥7 months), which was associated with a 25-percent risk increase for all-cause dementia and 34 percent for Alzheimer’s.

The potential of a higher risk of dementia should be investigated further and weighed against the benefits of ADT in the present population, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.